Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
Open Access
- 13 December 2010
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 152 (3) , 295-306
Abstract
Summary: The effects of two CD20 antibodies, namely rituximab, the current standard for treatment of chronic lymphocytic leukaemia (CLL) in combination with chemotherapy, and GA101, a glyco‐engineered type II antibody were compared on CLL cells ex vivo. Antibody‐induced phosphatidylserine exposure was examined in isolated CLL cells. For a more comprehensive assessment of antibody‐mediated cell killing including Fc‐mediated mechanisms, B cell depletion from whole blood samples was monitored. Treatment with rituximab or GA101 reduced the average viability of isolated CLL cells by 6% or 11%, and the ratio of B to T cells in whole blood samples by 12% or 33%, respectively. Combination with GA101 enhanced the cytotoxicity of the chemotherapeutic agent chlorambucil on isolated CLL cells. CD20 surface expression on CLL cells correlated with GA101‐induced B cell depletion, but not with direct cell death induction. Treatment of whole blood samples from CLL patients with a CpG‐containing oligonucleotide increased CD20 expression on CLL cells and GA101‐dependent B cell depletion. Despite the variable responses of individual CLL samples, the CLL cell depletion from whole blood by GA101 was consistently much stronger than by rituximab, which argues for clinical investigation of GA101 in CLL patients.Keywords
This publication has 41 references indexed in Scilit:
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Anti-CD20 monoclonal antibodies: historical and future perspectivesHaematologica, 2009
- An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing ChemotherapyClinical Cancer Research, 2009
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyBlood, 2009
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsBlood, 2008
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabLeukemia Research, 2008
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaBlood, 2008
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesCurrent Opinion in Immunology, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006